NCT00217737: A trial that was reported late by National Cancer Institute (NCI)
This trial has reported, although it was 94 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT00217737 |
|---|---|
| Title | A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Sept. 6, 2005 |
| Completion date | Feb. 22, 2024 |
| Required reporting date | Feb. 21, 2025, midnight |
| Actual reporting date | May 27, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 94 |